Nucleoside reverse transcriptase inhibitors (NRTIs)

APO LMV 300 Pill - gray four-sided

Pill with imprint APO LMV 300 is Gray, Four-sided and has been identified as Lamivudine 300 mg. It is supplied by Apotex Inc.

Lamivudine is used in the treatment of Hepatitis B; HIV Infection; Occupational Exposure; Nonoccupational Exposure and belongs to the drug class nucleoside reverse transcriptase inhibitors (NRTIs). Risk cannot be ruled out during pregnancy. Lamivudine 300 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images

Lamivudine (Lamivudine [ la-miv-ue-deen ])-APO LMV 300-300 mg-Gray-Four-sided
Lamivudine (Lamivudine [ la-miv-ue-deen ])-APO LMV 300-300 mg-Gray-Four-sided
Lamivudine (Lamivudine [ la-miv-ue-deen ])-APO LMV 300-300 mg-Gray-Four-sided
Lamivudine (Lamivudine [ la-miv-ue-deen ])-APO LMV 300-300 mg-Gray-Four-sided
Lamivudine (Lamivudine [ la-miv-ue-deen ])-APO LMV 300-300 mg-Gray-Four-sided

Lamivudine
Generic Name: lamivudine [ la-miv-ue-deen ]
Imprint: APO LMV 300
Strength: 300 mg
Color: Gray
Size: N/A
Shape: Four-sided
Availability: Prescription only
Drug Class: Nucleoside reverse transcriptase inhibitors (NRTIs)
Pregnancy Category: C - Risk cannot be ruled out
CSA Schedule: Not a controlled drug
Labeler / Supplier: N/A
National Drug Code (NDC): 60505-3252
Inactive Ingredients: Ferrosoferric oxide, Lactose anhydrous, Crospovidone, Silicon dioxide, Hypromelloses, Hydroxypropyl cellulose, Magnesium stearate, Polyethylene glycol, Titanium dioxide,
Latest News
Related Drugs